Author: claimsbot

1. A process for preparing a 1-olefin having from 8 to 16 carbon atoms by telomerization, comprising:
telomerizing a starting olefin having at least two conjugated bonds with a nucleophile in the presence of a palladium complex catalyst that contains at least one ligand which contains a carbene atom which is directly bonded to the palladium atom, hydrogenating the telomer obtained; and
subsequently cleaving the hydrogenated telomer to the 1-olefin.
2. The process as claimed in claim 1, wherein the carbene ligand comprise the structural element
wherein C is the carbene carbon which is bonded to the palladium atom.
3. The process as claimed in claim 2 wherein the carbene ligand is one or more compounds of formula I or II
wherein R2 and R3 are each, independently of one another, a linear, branched or cyclic C1-C24-alkyl group or a C5-C18-aryl group, where the alkyl group and the aryl group may bear, independently of one another, the substituents \u2014CN, \u2014COOH, \u2014COO-alkyl-(C1-C8), \u2014CO-alkyl -(C1-C8), -aryl-(C6-C18), -alkyl-(C1-C24), \u2014COO-aryl-(C6-C10), \u2014CO-aryl-(C6-C10), \u2014O-alkyl -(C1-C8), \u2014O\u2014CO-alkyl-(C1-C8), \u2014N-alkyl2-(C1-C8), \u2014CHO, \u2014SO3H, \u2014NH2, \u2014F, \u2014C1, \u2014OH, \u2014CF3, \u2014NO2, ferrocenyl, and R4 to R7 are each, independently of one another, hydrogen, \u2014CN, \u2014COOH, \u2014COO-alkyl-(C1-C8), \u2014CO-alkyl-(C1-C8), \u2014COO-aryl-(C6-C10), \u2014CO-aryl-(C6-C10), \u2014O-alkyl -(C1-C8), \u2014O\u2014CO-alkyl-(C1-C8), \u2014N-alkyl2-(C1-C8), \u2014CHO, \u2014SO3H, \u2014NH2, \u2014F, \u2014C1, \u2014OH, \u2014CF3, \u2014NO2 or a linear, branched or cyclic C1-C24-alkyl group or a C6-C18-aryl group and the alkyl group and aryl group may bear, independently of one another, the substituents \u2014CN, \u2014COOH, \u2014COO-alkyl-(C1-C8), \u2014CO-alkyl-(C1-C8), -aryl-(C6-C10), -alkyl-(C1-C24), \u2014COO-aryl-(C6-C10), \u2014CO-aryl-(C6-C10), \u2014O-alkyl-(C1-C8), \u2014O\u2014CO-alkyl-(C1-C8),\u2014N-alkyl2-(C1-C8), \u2014CHO, \u2014SO3H, \u2014NH2, \u2014F, \u2014C1, \u2014OH, \u2014CF3, \u2014NO2, and the radicals R4 and R5 may also be part of a bridging aliphatic or aromatic ring.
4. The process as claimed in claim 1, wherein said nucleophile is a compound of formulae III, IV or V
wherein R1 and R1\u2032 are selected independently from the group consisting of hydrogen, linear, branched or cyclic C1-C22-alkyl groups, alkenyl groups, alkynyl groups, carboxyl groups and C5-C18-aryl groups, where these groups may bear substituents selected from the group consisting of \u2014CN, \u2014COOH, \u2014COO-alkyl-(C1-C8), \u2014CO-alkyl -(C1-C8), -aryl-(C5-C10), \u2014COO-aryl-(C6-C10), \u2014CO-aryl-(C6-C10), \u2014O-alkyl-(C1-C8), \u2014O\u2014CO-alkyl-(C1-C8), \u2014N-alkyl2-(C1-C8), \u2014CHO, \u2014SO3H, \u2014NH2, \u2014F, \u2014C1, \u2014OH, \u2014CF3, \u2014NO2, and the radicals R1, R1\u2032 , may be linked to one another via covalent bonds.
5. The process as claimed in claim 1, wherein said nucleophile is methanol, ethanol, 2-ethylhexanol, octanol, octenol, octadienol, isopropanol, n-propanol, isobutanol, n-butanol, isononanol, formic acid, acetic acid, propionic acid, n-butanoic acid, isobutanoic acid, benzoic acid, phthalic acid, water, and mixtures thereof.
6. The process as claimed in claim 1, wherein the telomerization is carried out only to a conversion of the starting olefin of not more than 95%.
7. The process as claimed in claim 1, wherein the telomer is hydrogenated in the presence of a heterogeneous or homogeneous catalyst.
8. The process as claimed in claim 7, wherein said telomer is hydrogenated in the presence of a heterogeneous catalyst comprising at least one metal of groups 6-11 of the Periodic Table of the Elements.
9. The process as claimed in claim 8, wherein said hydrogenated telomer is cleaved in the presence of a basic or strongly basic or an acidic or strongly acidic catalyst.
10. The process as claimed in claim 9, wherein said hydrogenated telomer is cleaved in the presence of a catalyst comprising alkali metal hydroxidesoxides or alkaline earth metal hydroxidesoxides.
11. The process as claimed in claim 1, wherein said hydrogenated telomer is cleaved in the presence of a catalyst selected from the group consisting of alkali metal oxides, alkaline earth metal oxides, zinc oxide, aluminum oxide, yttrium oxide, lanthanum oxide, cerium oxide, thorium oxide, titanium oxide, zirconium oxide, tin oxide, alkali metal and alkaline earth metal carbonates, hydrogencarbonates or tungstates.
12. The process as claimed in claim 1, wherein said hydrogenated telomer is cleaved in the presence of a catalyst selected from the group consisting of hydrotalcites, mixed oxides of silicon andor aluminum with alkali metals and alkaline earth metals, zinc, thorium, titanium, zirconium, tungsten, tin and molybdenum.
13. The process as claimed in claim 1, wherein the cleavage of the hydrogenated telomer is carried out in the gas phase.
14. The process as claimed in claim 13 wherein the cleavage of the hydrogenated telomer is carried out at temperatures in the range from 100 to 800\xb0 C.
15. The process as claimed in claim 1, wherein the cleavage of the hydrogenated telomer is carried out to a conversion of the hydrogenated telomer of 10-95%.
16. The process as claimed in claim 1, wherein 1,3-butadiene or isoprene is the starting olefin having at least two conjugated double bonds.
17. The process as claimed in claim 16, wherein the starting olefin is admixed with other hydrocarbons.
18. The process as claimed in claim 1, wherein the telomerization is carried out at temperatures ranging from 10 to 180\xb0 C. and a pressure of from 1 to 300 bar.
19. The process as claimed in claim 1, wherein the ratio of carbene ligand to Pd (molmol) ranges from 0.01:1 to 250:1.
20. The process as claimed in claim 1, wherein the palladium-carbene complex is introduced as such into the telomerization reaction.
21. The process as claimed in claim 1, wherein the palladium-carbene complex is generated in situ during the telomenzation reaction.
22. The process as claimed in claim 1, wherein the carbene ligand is generated in situ during the telomerization reaction.
23. The process as claimed in claim 1, wherein a basic component having a pKb of <7 is added to the telomerization reaction.
24. The process as claimed in claim 1, wherein the palladium concentration in the reaction mixture of the telomerization ranges from 0.01 to 1000 ppm.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1-20. (canceled)
21. A programmable logic device configuration comprising:
an application logic;
an embedded test logic that monitors the application logic to produce embedded test data;
an encryption logic, said encryption logic encrypting said embedded test data;
a memory for storing an access key; and
an access control logic that grants an external device access to said encrypted embedded test data based upon the stored access key and data received from the external device.
22. The programmable logic device configuration of claim 21, further comprising:
a decryption logic, said decryption logic decrypting encrypted data received from said external device.
23. The programmable logic device configuration of claim 22, wherein said stored access key is used to decrypt said encrypted data.
24. The programmable logic device configuration of claim 21, wherein said stored access key is used to encrypt said embedded test data.
25. The programmable logic device configuration of claim 21, wherein said external device interfaces with said programmable logic device using at least one of a Joint Test Action Group port, a configuration access port, or an inputoutput port.
26. The programmable logic device configuration of claim 21, further comprising:
a Joint Test Action Group logic.
27. The programmable logic device configuration of claim 26, wherein said access control logic provides an access control layer between said Joint Test Action Group logic and said embedded test logic.
28. The programmable logic device configuration of claim 21, further comprising:
a second memory for storing normal embedded test data values; and
a health monitor logic for monitoring actual values of said embedded test data relative to said normal embedded test data values.
29. The programmable logic device configuration of claim 28, wherein said health monitor logic provides a warning to said external device when said actual values of said embedded test data are determined to be unacceptable when compared to said normal embedded test data values.
30. A method for programming a configuration of a programmable logic device comprising the steps of:
creating on the programmable logic device an application logic;
creating on the programmable logic device an embedded test logic that monitors the application logic to produce embedded test data;
creating on the programmable logic device an encryption logic, said encryption logic encrypting said embedded test data; and
creating on the programmable logic device an access control logic that grants an external device access to said encrypted embedded test data based upon an access key stored in a memory and data received from the external device.
31. The method of claim 30, further comprising the step of:
creating on the programmable logic device a decryption logic, said decryption logic decrypting encrypted data received from said external device.
32. The method of claim 31, wherein said decryption logic uses said stored access key to decrypt said encrypted data.
33. The method of claim 30, wherein said encryption logic uses said stored access key to encrypt said embedded test data.
34. The method of claim 30, further comprising:
creating on the programmable logic device a Joint Test Action Group logic.
35. The method of claim 34, wherein said access control logic provides an access control layer between said Joint Test Action Group logic and said embedded test logic.
36. The method of claim 30, further comprising:
creating on the programmable logic device a health monitor logic for monitoring actual values of said embedded test data relative to normal embedded test data values stored in a second memory.
37. The method of claim 36, wherein said health monitor logic provides a warning to said external device when said actual values of said embedded test data are determined to be unacceptable when compared to said normal embedded test data values.
38. The method of claim 37, further comprising:
creating on the programmable logic device an encryption logic, said encryption logic encrypting said warning.
39. A method for protecting embedded test data of a programmable logic device comprising the steps of:
creating on the programmable logic device an encryption logic, said encryption logic encrypting said embedded test data; and
creating on the programmable logic device an access control logic that grants an external device access to said encrypted embedded test data based upon an access key stored in a memory and data received from the external device.
40. The method of claim 39, wherein said encryption logic uses said stored access code to encrypt said embedded test data.

1. A wind turbine for extracting energy out of an airflow, the wind turbine having an axis of rotation, the wind turbine comprising:
turbine blades mounted for axial rotation and having a swept area;
a first shroud surrounding the turbine blades and defining a first axial air passage, the first shroud having an upstream opening and a downstream opening, the first shroud having photovoltaic cells on an outward facing surface thereof;
a plurality of plates attached to the first shroud, the plates spaced radially outward from the first shroud, the plates spaced around the circumference of the first shroud and projecting beyond the downstream opening of the first shroud, the plurality of plates forming a second discontinuous shroud; the first shroud and the plurality of plates forming a second axial air passage between the first shroud and plurality of plates, the plurality of plates having photovoltaic cells on an outward facing surface thereof;
the plurality of plates having gaps between adjacent plates such that air exiting the downstream opening of the first shroud and air moving through the second axial air passage are mixed and a portion of the mixed air exits through the gaps, such that the rotation of the turbine blades and the photovoltaic cells generate electricity.
2. The wind turbine of claim 1 wherein the ratio of the total area of the plates to the total area of the gaps is between 8:1 and 1:1.
3. The wind turbine of claim 1 wherein the ratio of the total area of the plates to the total area of the gaps is approximately 3:1.
4. The wind turbine of claim 1 further including a ring mounted near the downstream end of the plates and spaced radially outward from the plates to create a third axial air passage between the ring and the plates.
5. The wind turbine of claim 4 wherein the ring is continuous.
6. The wind turbine of claim 4 wherein the ring is discontinuous.
7. The wind turbine of claim 1 wherein the plates extend from a location near the upstream opening of the shroud to a location beyond the downstream opening of the shroud.
8. The wind turbine of claim 1 wherein the plates extend from a location near the midpoint between the upstream opening of the shroud and the downstream opening of the shroud to a location beyond the downstream opening of the shroud.
9. The wind turbine of claim 1 wherein the plates are arcuate in shape.
10. The wind turbine of claim 1 wherein the plates have a curvature generally corresponding to the shroud.
11. The wind turbine of claim 1 wherein the first shroud is conical.
12. The wind turbine of claim 1 wherein the plates have a width which increases in the direction of the airflow.
13. The wind turbine of claim 1 wherein the number of blades is between 3 and 20.
14. The wind turbine of claim 1 wherein the photovoltaic cells are attached to the plates by a fastener.
15. The wind turbine of claim 1 wherein the photovoltaic cells are bonded to the plates.
16. A wind turbine for extracting energy out of an airflow, the wind turbine having an axis of rotation, the wind turbine comprising:
turbine blades mounted for axial rotation about a hub, the blades having a swept area;
a first cylindrical shroud surrounding the turbine blades and defining a first axial air passage, the first cylindrical shroud having an upstream opening and a downstream opening, the first cylindrical shroud having photovoltaic cells on an outward facing surface thereof;
a plurality of plates attached to the first cylindrical shroud, the plates spaced radially outward from the first cylindrical shroud, the plates spaced around the circumference of the first cylindrical shroud and projecting beyond the downstream opening of the first cylindrical shroud, the plurality of plates forming a second discontinuous shroud; the first cylindrical shroud and the plurality of plates forming a second axial air passage between the first cylindrical shroud and plurality of plates, the plurality of plates having photovoltaic cells on an outward facing surface thereof;
the plurality of plates having gaps between adjacent plates such that air exiting the downstream opening of the first cylindrical shroud and air moving through the second axial air passage are mixed and a portion of the mixed air exits through the gaps, such that the rotation of the turbine blades and the photovoltaic cells generate electricity.
17. The wind turbine of claim 16 wherein the ratio of the total area of the plates to the total area of the gaps is between 8:1 and 1:1.
18. The wind turbine of claim 16 wherein the ratio of the total area of the plates to the total area of the gaps is approximately 3:1.
19. The wind turbine of claim 16 further including a ring near the downstream end of the plates and spaced radially outward from the plates to create a third axial air passage between the ring and the plates.
20. The wind turbine of claim 19 wherein the ring is continuous.
21. The wind turbine of claim 19 wherein the ring is discontinuous.
22. The wind turbine of claim 16 wherein the plates extend from a location near the upstream opening of the cylindrical shroud to a location beyond the downstream opening of the cylindrical shroud.
23. The wind turbine of claim 16 wherein the plates extend from a location near the midpoint between the upstream opening of the cylindrical shroud and the downstream opening of the cylindrical shroud to a location beyond the downstream opening of the cylindrical shroud.
24. The wind turbine of claim 16 wherein the plates are arcuate in shape.
25. The wind turbine of claim 16 wherein the plates have a curvature generally corresponding to the shroud.
26. The wind turbine of claim 16 wherein the plates have a width which increases in the direction of the airflow.
27. The wind turbine of claim 16 wherein the number of blades is between 3 and 20.
28. The wind turbine of claim 16 wherein the number of blades is 6.
29. The wind turbine of claim 16 wherein the plates are angled away from the axis of rotation at an angle of between 0 degrees and 40 degrees.
30. The wind turbine of claim 16 wherein the photovoltaic cells are attached to the plates by a fastener.
31. The wind turbine of claim 16 wherein the photovoltaic cells are bonded to the plates.
32. A wind turbine for extracting energy out of an airflow, the wind turbine having an axis of rotation, the wind turbine comprising:
turbine blades mounted for axial rotation, the blades having a swept area;
a first shroud surrounding the turbine blades and defining a first axial air passage, the first shroud having an upstream opening and a downstream opening, the first shroud constructed from flexible photovoltaic cells;
a plurality of plates, constructed from photovoltaic cells, attached to the first shroud, the plates spaced around the circumference of the first shroud and projecting beyond the downstream opening of the first shroud, the plurality of plates forming a second discontinuous shroud;
the plurality of plates having gaps between adjacent plates such that a portion of the air exiting the downstream opening of the first shroud exits through the gaps, the plurality of plates constructed from flexible photovoltaic cells such that the rotation of the turbine blades and the photovoltaic cells generate electricity.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A system for modeling and predicting anesthesia drug effects on a patient, comprising:
a drug delivery system configured to deliver anesthesia drugs into the patient;
a data stream device, in communication with the drug delivery system
a simulator in communication with the drug delivery system, the simulator being configured to simulate drug administration effects and simulate infusion drugs by representing drug effects over time as a multi-dimensional visualization;
a drug display monitor in communication with the data stream device and including:
a data decoder receiving data from the data stream device;
a dosage calculator receiving decoded data from the data decoder;
a drug modeler and normalizer receiving calculated data from the data decoder;
the drug modeler configured to determine a present and future probability of effectiveness of at least one drug introduced into the subject by the drug delivery system, wherein the present and future probabilities of drug effectiveness include a correlation of modeled pharamacokinetic data and modeled pharmacodynamic data; and

a display generator that produces a display of:
the present and future probabilities of effectiveness including predicted pharamacokinetic effect side concentrations depicted as a percent of a concentration value corresponding to a known pharmacodynamic probability of causing a particular bodily effect;
a three-dimensional plot configured to provide a three-dimensional view of the effect of interactions of at least two anesthesia medicines;

a bar graph and drug synergism is shown as an additional bar on the bar graph representing the additional effect on the patient due to drug interactions as the simulator simulates anesthetic drugs from the multi-dimensional visualization
a probability of effectiveness of at least one drug administered, including at least one of:
a probability that a subject will be rendered unconscious by at least one drug having a sedative effect;
a probability that a subject will not exhibit pain from laryngoscopy, incision, or post-operative recovery of surgery by at least one drug having and analgesic effect; and a probability that a subject will not exhibit a response to a train-of-four electrical muscle stimulation by at least one drug having a neuromuscular blocking effect, the probability of effectiveness determined based upon the model.
2. The system recited in claim 1, wherein the drug delivery system includes:
an infusion pump;
an anesthetic administration machine; and
one or more bar coded syringes.
3. The system recited in claim 1,
wherein the drug delivery system includes a simulator, which simulates drug effects.
4. The system recited in claim 3,
wherein the simulator simulates bolus drugs, infusion drugs, anesthetic drugs, sedative drugs, analgesic drugs and neuromuscular blocking drugs.
5. A system for modeling and predicting anesthesia drug effects on a patient, comprising:
a processor, computing drug models, producing an internal representation of drug display data and decoding a data stream, wherein the processor is configured to determine a present and future probability effectiveness of at least one drug introduced into the subject by the drug delivery system, wherein the present and future probabilities of effectiveness include a correlation of a predicted drug effect site concentration based on modeled pharmacokinetic data and modeled pharmacodynamic data;
wherein the future probability of effectiveness of the at least one drug is represented in real time, comprising:
(A) a graph depicting a probability of effectiveness of at least one sedative, referenced according to a measure of consciousness;
(B) a graph depicting a probability of effectiveness of at least one analgesic, referenced according to a measure of surgical stimuli and according to a measure of laryngoscopy; and
(C) a graph depicting a probability of effectiveness of at least one neuromuscular blocking agent, referenced according to a measure of neuromuscular blocking,

a memory unit in communication with the processor;
a long term memory unit in communication with the processor;
a graphics adapter in communication with the processor; and
a display monitor, in communication with the graphics adapter, configured to graphically depict:
a mode of administration of at least one drug, with different modes of administration being readily identifiable and readily distinguishable from one another,
a three-dimensional plot configured to provide a three-dimensional view of the effect of interactions of at local two anesthesia medicine;
a bar graph wherein drug synergism is shown as an additional bar on the bar graph representing the additional effect on the patient due to drug interactions; and further configured to depict, in substantially real time, the present and future probabilities of effectiveness including predicted pharmacokinetic effect site concentrations depleted as a percent of a concentration value corresponding to a known pharmacodynamic probability of causing a particular bodily effect.
6. The system recited in claim 5,
wherein the display monitor is configured to depict a graph representing an additional effect,
wherein the additional effect results from drug interactions, comprising a system for executing a multi-dimensional pharmacodynamic mathematical model to simulate the interactive pharmacokinetic and pharmacodynamic effects between sedatives and analgesics.
7. The system recited in claim 6, wherein the processor processes:
information regarding receiving the potency of a drug;
a calculator calculating the relative potency of a drug in a class of drugs; and
a merge function combining the relative potencies of two or more drugs to calculate the total effect of the two or more drugs.
8. The system recited in claim 5,
wherein the display monitor is configured to depict a graph representing an additional effect,
wherein the additional effect results from drug interactions, comprising a system for data representation that maps multi-dimensional drug effect surfaces, generated by a pharmocodynamic model, to a respective graph of the drug class with sedative and analgesia drug effect site concentrations as input.
9. The system recited in claim 8, wherein the processor processes:
information relating the sedative and analgesic volumes of a drug;
a calculator for calculating a combination effect of the drug with other drugs; and
a correlator for mapping the combination effect to a two-dimensional graph.
10. The system recited in claim 5, wherein the display monitor is configured to depict a graph representing an additional effect, wherein the additional effect results from drug interactions, comprising a system for differentiating the individual and interactive components for estimated drug effects in the data representation.
11. The system recited in claim 10, further comprising: a calculator for calculating an effect of a first drug acting alone; a display for displaying a first drug effect; a calculator for calculating an effect of a second drug acting alone; a display for displaying the second drug effect; a calculator for calculating a combined effect of the first and the second drug effects; and a display for displaying the combined effect.
12. The system recited in claim 1, wherein the display generator produces a display of probabilities of effectiveness of at least two drug effects.
13. The system recited in claim 1, wherein the display generator produces a display of probabilities of effectiveness of at least two drugs.
14. The system recited in claim 13,
wherein the display generator produces a display of probabilities of effectiveness of at least one sedative, at least one analgesic, and at least one neuromuscular blocker.
15. A method for modeling and predicting drug anesthesia drug effects on a patient, comprising:
determining a present and future probability of effectiveness of at least one drug introduced into a subject by a drug delivery system, wherein the present and future probabilities of effectiveness include a correlation of a predicted drug effect site concentration based on modeled pharmacokinetic data and a probability of achieving a bodily effect on the patient based on modeled pharmacodynamic, pharmacokinetic and pharmacodynamic drug interactions, and a predictive pharmacodynamic model including a three-dimensional surface developed from data corresponding to pharmacodynamic effectiveness of the at least one drug on a plurality of individuals to whom the at least one drug was previously administered;
converting the three-dimensional surface to a simplified two-dimensional model;
displaying a bar graph and drug synergism is shown as an additional bar on the bar graph representing the additional effect on the patient due to drug interactions; and
displaying the two-dimensional model on a display; including at least one indicator of the probability of effectiveness of the at least one drug and including predicted pharamacokinetic effect site concentrations depicted as a percent of a concentration value corresponding to a known pharmacodynamic probability of causing a particular bodily effect, wherein the two-dimensional model includes indicators of at least one of:
a probability that a subject will be rendered unconscious by at least one drug having a sedative effect;
a probability that a subject will not exhibit pain from laryngoscopy, incision, or post-operative recovery of surgery by at least one drug having and analgesic effect; and
a probability that a subject will not exhibit a response to a train-of-four electrical muscle stimulation by at least one drug having a neuromuscular blocking effect.
16. The method recited in claim 15, wherein displaying comprises displaying the two-dimensional model with indicators of probabilities of different levels of effectiveness.
17. The method recited in claim 16, wherein displaying comprises displaying the two-dimensional model with indicators of probabilities that a subject will not exhibit pain from at least two of laryngoscopy, incision, and post-operative recovery of surgery.
18. The system recited in claim 5, wherein the mode of administration the at least one drug comprises a bolus which is represented as a vertical bar.
19. The system recited in claim 18, wherein a height of the vertical bar represents an amount of the at least one drug administered to a subject.
20. The system recited in claim 5, wherein the mode of administration of the at least one drug comprises infusion, which is represented as a horizontal line.
21. The system recited in claim 20, wherein a length of the horizontal line represents a duration of the infusion.
22. The system recited in claim 20, wherein at least one of a thickness and a vertical location of the horizontal line represents an amount of the infusion.
23. The system recited in claim 1, wherein the drug modeler and normalizer is further configured to normalize the individual drug concentrations based on a pharmacodynamic value.
24. The system recited in claim 23, wherein the pharamacodynamic value is the value at which 95% of the population would experience a particular pharmacodynamic effect corresponding to the classification of the corresponding individual drug.
25. The system recited in claim 1, wherein the present and future probability of effectiveness of at least drug introduced into the subject by the drug delivery system is based on a correlation of all of the individual drug concentrations, drug interactions, and the pharmacodynamic effectiveness data previously obtained from a plurality of individuals.
26. The system recited in claim 5, wherein the depicted modes of administration include a bolus injection and an infusion pump.
27. The system recited in claim 5, wherein the present and future probability of effectiveness of at least drug introduced into the subject by the drug delivery system is based on a correlation of all of the individual drug concentrations, drug interactions, and the pharmacodynamic effectiveness data previously obtained from a plurality of individuals.